


## 1-Naphthohydroxamic acid

<b>Cat. No.:</b>	HY-130538		
<b>CAS No.:</b>	6953-61-3		
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>9</sub> NO <sub>2</sub>		
<b>Molecular Weight:</b>	187.19		
<b>Target:</b>	HDAC		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (667.77 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	5.3422 mL	26.7108 mL	53.4217 mL
	5 mM	1.0684 mL	5.3422 mL	10.6843 mL
	10 mM	0.5342 mL	2.6711 mL	5.3422 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC<sub>50</sub> of 14 μM. 1-Naphthohydroxamic acid is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC<sub>50</sub> >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity<sup>[1][2]</sup>. 1-Naphthohydroxamic acid can induce tubulin acetylation<sup>[3]</sup>.

#### IC<sub>50</sub> & Target

HDAC8 14 μM (IC <sub>50</sub> )	HDAC1 >100 μM (IC <sub>50</sub> )	HDAC6 >100 μM (IC <sub>50</sub> )
------------------------------------	--------------------------------------	--------------------------------------

#### In Vitro

1-Naphthohydroxamic acid (compound 2; 20-40 μM; 0-144 hours; BE(2)-C, SK-N-BE(2) and SH-SY5Y cells) treatment reduces cell numbers in a concentration-dependent manner<sup>[2]</sup>.

1-Naphthohydroxamic acid (compound 2) at concentrations in the range of its in vitro IC<sub>50</sub> against HDAC8 results in reduced cell density and outgrowth of neurite-like structures that stained positive for neurofilament. 1-Naphthohydroxamic acid reduces the formation of clones in soft-agar concentration dependently<sup>[2]</sup>.

When either cell type (HeLa and HEK293 cells) is treated with 1-Naphthohydroxamic acid (compound 2; 0.8 μM, 4 μM, 20 μM or 100 μM), only tubulin becomes hyperacetylated<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Proliferation Assay<sup>[2]</sup>

Cell Line:	BE(2)-C, SK-N-BE(2) and SH-SY5Y cells
Concentration:	20 $\mu$ M, 40 $\mu$ M
Incubation Time:	0 hours, 24 hours, 48 hours, 72 hours, 96 hours, and 144 hours
Result:	Reduced cell numbers in a concentration-dependent manner.

#### In Vivo

Dose-limiting toxicities (DLTs) of 1-Naphthohydroxamic acid (compound 2; 0-40 mg/kg; intraperitoneal injection; daily; for 10 day; NMRI Foxn1 nude mice) include weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. 1-Naphthohydroxamic acid has the maximum tolerable doses at 50 mg/kg per day. At these concentrations, neither body weight nor blood parameters are critically changed<sup>[3]</sup>.

Pharmacokinetic studies after intraperitoneal administration of the inhibitors identified the half-life of 1-Naphthohydroxamic acid to be ~15 min, with a plasma peak concentration of ~30  $\mu$ M<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NMRI Foxn1 nude mice <sup>[3]</sup>
Dosage:	0 mg/kg, 50 mg/kg, 100mg/kg, 200 mg/kg, 300 mg/kg 400 mg/kg
Administration:	Intraperitoneal injection; daily; for 10 days
Result:	Dose-limiting toxicities (DLTs) included weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination.

## REFERENCES

- [1]. Krennhrubec K, et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. *Bioorg Med Chem Lett*. 2007 May 15;17(10):2874-8.
- [2]. Oehme I, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. *Clin Cancer Res*. 2009 Jan 1;15(1):91-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA